文献库 文献相关信息

题目:
Outcomes of women with metachronous breast and ovarian carcinomas.
作者:
Liou(Wen-Shiung),Hamilton(Chad A),Cheung(Michael K),Osann(Kathryn),Longacre(Teri A),Teng(Nelson N),Husain(Amreen),Dirbas(Frederick M),Chan(John K)
状态:
发布时间2006-09-19 , 更新时间 2006-09-19
期刊:
Gynecol Oncol
摘要:
Women with a history of breast cancer have a significantly increased risk of developing a second primary ovarian cancer and vice versa. We proposed to determine the characteristics and outcomes of women diagnosed with metachronous breast and ovarian cancer.,Patients were identified from the Surveillance, Epidemiology, and End Results program database between 1988 and 2001. Kaplan-Meier and Cox proportional hazards regression tests were used to determine survival outcomes.,Of 704 women, 526 developed breast cancer then ovarian cancer (B-O) and 178 developed ovarian cancer then breast cancer (O-B). The mean age at diagnosis of the first cancer in the B-O versus O-B group was 60.3 versus 58.9 years, respectively (P = 0.23). Twenty-five percent of women in the B-O group had stage I-II ovarian cancer versus 63% in the O-B group (P < 0.001). The percentage of those with stage I-II breast cancer was 94% and 91% in the B-O versus O-B group, respectively (P = 0.13). Women in the B-O group had more high grade of ovarian cancer compared to those in the O-B group (P < 0.001). The mean time interval between diagnoses of breast then ovarian versus ovarian then breast cancer was 58 versus 56 months, respectively (P = 0.42).,In the largest series to date, we found that women diagnosed with ovarian cancer first had significantly more early stage and lower grade ovarian cancers with better survival compared to those with breast cancer followed by ovarian cancer. Since half of the women had their second cancer beyond 5 years, continued surveillance of these high risk patients is recommended.
语言:
eng
DOI:
10.1016/j.ygyno.2006.02.022

联系方式

山东省济南市章丘区文博路2号 齐鲁师范学院 genelibs生信实验室

山东省济南市高新区舜华路750号大学科技园北区F座4单元2楼

电话: 0531-88819269

E-mail: product@genelibs.com

微信公众号

关注微信订阅号,实时查看信息,关注医学生物学动态。